Thus, changes in energy-related metabolic pathways may provide growth advantages to tumour cells and support aggressive tumour phenotypes, and STAT1 may be a valuable target for antitumour therapy directed towards energy depletion of proliferating tumour cells. This evidence concerns the gene STAT1 and neoplasm.